Major Depressive Disorder Clinical Trial
Official title:
Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting
The goal of the study is to address the unmet need of TRD patients by identifying brain
networks critical for treating depression and to use next generation precision DBS with
steering capability to engage these targeted networks. The study's goal will be achieved
through 3 specific aims:
Demonstrate device capability to selectively and predictably engage distinct brain networks
Delineate depression-relevant networks and demonstrate behavioral changes with
network-targeted stimulation Demonstrate that chronic DBS using steered, individualized
targeting is feasible and safe for reducing depressive symptoms
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | September 30, 2024 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Men and women (non-pregnant) between ages 22 and 70; 2. DSM-5 diagnosis (assessed by Structured Clinical Interview for DSM-5 Axis I disorders SCID-5) of major depression disorder (MDD) as the primary diagnosis. A current major depressive episode (MDE), recurrent or single episode with first episode before age 60, secondary to nonpsychotic unipolar major depressive disorder; 3. Chronic illness with current MDE =24 months duration and/or recurrent illness with at least a total of 2 lifetime episodes (including current episode >12 months); 4. Treatment resistance (defined by criteria on the Antidepressant Treatment History Form ATHF): Failure (i.e. persistence of the major depressive episode) to respond to a minimum of four adequate depression treatments from at least two different treatment categories (e.g. SSRIs, SNRIs, TCAs, other antidepressants, lithium-addition, irreversible MAOIs, antidepressant augmentation with an atypical antipsychotic medication); 5. Previous trial of Electroconvulsive Therapy (ECT) (lifetime): either did not respond, relapsed, poorly tolerated or refused. If refused, will discuss reasons and ensure subject understands relative risks of ECT versus DBS. We will try to enrich sample with patients who had previously shown response to ECT (or another intervention) that was partial or un-sustained; 6. A prior trial of ketamine will not be required because it is not FDA approved and durable responses have not been demonstrated, nevertheless, subjects will be informed about this possible off-label option; 7. Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17) =20; 8. The HDRS17 must remain greater than or equal to 20 on two separate assessments (at initial screening and 1 week before surgery), over a 1-month period; 9. Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) =27 to be met at assessment one-week pre-op; 10. Lifetime exposure to minimal 6 weeks of psychotherapy without sustained response; 11. Normal brain MRI within 3 months of surgery; 12. Stable antidepressant medication regimen for the month preceding surgery; 13. Modified mini-mental state examination (MMSE) score = 24; 14. Normal thyroid stimulating hormone (TSH) level within 12 months of study entry; 15. Other medical conditions must be stable for at least 6 months; 16. Able and willing to give informed consent and agree to attend regular clinic visits for at least 12 months following surgery; 17. Able to have a treating psychiatrist or close relative present for discussions about the study and co-sign informed consent; 18. Willingness to sign Treatment Contract Exclusion Criteria: 1. DSM-5 Axis I Disorders: any lifetime history of psychotic disorder (e.g., schizophrenia, schizoaffective disorder); 2. Bipolar disorder with rapid cycling and history of manic episode requiring hospitalization within the past 5 years; 3. Clinically significant Cluster A or B personality disorder; 4. Active alcohol or substance use disorder within 6 months, excluding nicotine; 5. Urine drug test positive for illicit drugs; 6. Current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or made a suicide attempt within the last year; or as identified as C-SSRS; 7. Neurological/Medical condition that makes the patient, in the opinion of the surgeon, a poor surgical candidate (e.g., progressive neurodegenerative disorder, significant cardiopulmonary disorder, need for chronic anticoagulation); 8. Any history of seizure disorder or hemorrhagic stroke; 9. Any medical contraindication to surgery such as infection; 10. Coagulopathy: Bleeding propensity and/or one of the following: INR > 1.5; prolonged activated partial thromboplastin time (aPTT) = 45 sec; platelet count < 100×103/uL; 11. Uncontrolled hypertension (systolic > 185 mmHg and/or diastolic > 110 mmHg), demonstrated on each of three repeated measurements taken within one hour regardless of whether or not the patient is taking antihypertensive medications. 12. Participation in another drug, device, or biological trial within 90 days; 13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators including spinal cord stimulators and deep brain stimulators; 14. Pregnant or has plans to become pregnant in the next 24 months; 15. Anticipated need for MRI; 16. Need for Diathermy. |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine | Houston | Texas |
United States | University of California, Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in depressive symptoms | Response will be defined as 50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline. The range is from 0 to 60 and a score higher than 20 indicates moderate to severe depression. | 54 to 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |